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Abstract
Vaccinia virus (VACV) is a large, cytoplasmic, double-stranded DNA virus that requires complex interactions with host
proteins in order to replicate. To explore these interactions a functional high throughput small interfering RNA (siRNA)
screen targeting 6719 druggable cellular genes was undertaken to identify host factors (HF) influencing the replication and
spread of an eGFP-tagged VACV. The experimental design incorporated a low multiplicity of infection, thereby enhancing
detection of cellular proteins involved in cell-to-cell spread of VACV. The screen revealed 153 pro- and 149 anti-viral HFs that
strongly influenced VACV replication. These HFs were investigated further by comparisons with transcriptional profiling data
sets and HFs identified in RNAi screens of other viruses. In addition, functional and pathway analysis of the entire screen was
carried out to highlight cellular mechanisms involved in VACV replication. This revealed, as anticipated, that many pro-viral
HFs are involved in translation of mRNA and, unexpectedly, suggested that a range of proteins involved in cellular
transcriptional processes and several DNA repair pathways possess anti-viral activity. Multiple components of the AMPK
complex were found to act as pro-viral HFs, while several septins, a group of highly conserved GTP binding proteins with a
role in sequestering intracellular bacteria, were identified as strong anti-viral VACV HFs. This screen has identified novel and
previously unexplored roles for cellular factors in poxvirus replication. This advancement in our understanding of the VACV
life cycle provides a reliable knowledge base for the improvement of poxvirus-based vaccine vectors and development of
anti-viral theraputics.
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Introduction
Vaccinia virus (VACV) is a large double-stranded DNA virus with
a complex cytoplasmic life cycle. It is the prototypical member of
the orthopoxviridae genus of the Poxviridae family which includes
Variola virus (the causative agent of smallpox), Monkeypox virus and
Ectromelia virus. VACV was used as a vaccine in the successful
global eradication of smallpox in the 20th century and closely
related attenuated strains such as Modified Vaccinia virus Ankara
(MVA) are now some of the most frequently used recombinant
vaccine vectors against a variety of human and animal diseases
including HIV, malaria and tuberculosis [1]. Understanding the
VACV life cycle is therefore important since it provides the base
for the development of efficient and safe novel vaccines.
VACV, like all other viruses, harnesses the cell to enable its
replication. It turns off or subverts multiple crucial anti-viral
pathways including cytokine production, Toll-like receptor path-
ways, NF-kB activation and the dsRNA PKR response [2–8]. In
addition VACV suppresses both intrinsic and extrinsic pro-
apoptotic pathways [9] and activates numerous anti-apoptotic,
pro-survival pathways including the PI3K/Akt pathway [10,11],
the MEK/ERK pathway [12,13], the p38 MAPK pathway [14]
and the MAPK/JNK pathway [14,15]. Modulation of so many
different signalling pathways prevents viral-induced premature cell
death and contributes to the ability of poxviruses to replicate in a
wide range of cell types.
To investigate this complex pathogen-host relationship further,
a RNAi screen of druggable host targets was carried out to analyse
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the effect of cellular protein depletion on VACV replication, using
a multi-cycle VACV infection assay that monitors all stages of
virus replication including virus spread. The screen identified a
range of previously identified HFs, but also novel HFs and
pathways influencing VACV infection that may facilitate the
development of broadly effective anti-viral strategies and the
optimisation of poxviral-based vaccine vectors.
Materials and Methods
RNA Interference Screen
A schematic diagram of the workflow used in the RNAi screen is
shown in Figure 1. siRNA SMARTpools (4 siRNAs per gene,
Dharmacon) were diluted to 0.3 mM and dispensed in 10 ml
volumes using a Rapidplate384 liquid handler (Qiagen) into eight
black 384-well plates (Corning). These were stored at 280uC until
needed (maximum 48 h). On the day of transfection, plates were
thawed and 10 ml transfection reagent (Dharmafect 1, Dharma-
con) diluted in Hank’s buffered saline solution (HBSS, Thermo-
Fisher) was added to each well containing siRNA using a
Multidrop 384 (ThermoFisher), to give a final transfection reagent
concentration of 0.1%. Plates were incubated for 20 min at room
temperature to allow formation of transfection complexes. During
complex formation, low-passage (p20–22) HeLa cells (ECACC)
from approximately 50% confluent flasks were washed in PBS and
trypsinised in Trypsin-EDTA (Lonza) before diluting in phenol
red-free, antibiotic-free transfection medium (DMEM/F-12 1:1
with 5% FCS, 15 mM Hepes and L-glu; Gibco). 36103 cells in a
volume of 40 ml were added to each well using the Multidrop 384.
Plates were incubated for 48 h at 37uC in a humidified incubator
with 5% CO2 before infection. To infect, media was removed
from plates by inversion, and 15 ml media (DMEM +4.5 g/L D-
glucose, L-glu and pyruvate with 2.5% FCS and penicillin-
streptomycin) or 15 ml media containing VACV strain WR with
eGFP tagged A5 protein [16] diluted to MOI 0.05, was added
using the Multidrop 384. Plates were incubated at 37uC for 1 h
before 50 ml of media was added to each well, the plates inverted
to remove the media and virus, and a final volume of 50 ml of
media added to the plates before they were returned to the
incubator. After 48 h the plates were inverted to remove the media
and 50 ml of 10% buffered formal saline added to fix the cells.
Fluorescence levels were measured using a POLARstar OPTIMA
plate reader (BMG Labtech). Data from eight replicates was used
for analysis. Background intensity correction was carried out by
subtracting the median value of uninfected wells and the data was
normalised using the robust Z score method [17], and corrected
for the number of cells in each well. The correction for the number
of cells in each well was carried out by estimating the linear
correlation coefficient between the level of fluorescence (pheno-
type score) and the number of cells (toxicity score) using least
squares optimization. This coefficient was used to linearly adjust
the phenotype scores.
High Content Screening
One replicate of the screen was imaged by a high content
screening system. The buffered formal saline was removed from
the cells by inverting the plates, and cells were washed in 50 ml of
room temperature PBS before permeabilising for 15 min at room
temperature in 30 ml of 0.1% tritonX-100 diluted in PBS. Plates
were inverted and 50 ml of a 1:50 dilution of AlexaFluor-647
phalloidin (Invitrogen Molecular Probes) diluted in PBS + 1%
BSA was added and incubated for 45 min in the dark. The
phalloidin was removed by inversion and 50 ml of DAPI (1 mg/ml)
diluted in PBS was added and left on. Cells were analysed by
automated microscopy using an OPERA high content screening
system (Perkin Elmer) and Acapella High Content Imaging and
Analysis software.
Definition of Toxic siRNA Pools
To identify siRNA SMARTpools which exerted significantly
toxic effects the number of cells in each well was counted and
converted to a z-score. A z-score is equivalent to the number of
standard deviations away from the mean. siRNA treatments that
reduced the cell number by two or more standard deviations
below the population mean (z-score of 22 or less) were removed
from further analysis. A z-score of 22 was equivalent to 250 cells,
compared to a population mean of 455.
qPCR Confirmation of siRNA Knockdown
Selected siRNA SMARTpools were diluted to 0.3 mM in 1x
siRNA buffer and dispensed in triplicate in 96-well plates
(Corning). To this, 10 ml Dharmafect 1 diluted in DMEM to give
a final concentration of 0.15% was added using the Multidrop
384. Following a 20 min incubation to enable complex formation,
0.46104 Hela cells in 80 ml transfection media were added and
plates were transferred to a 37uC humidified incubator with 5%
CO2. After 48 h, medium was removed and cells rinsed in PBS
before lysing in 100 ml TRIZOL (Invitrogen). Triplicate wells were
combined, and RNA extracted by PureLink (TM) RNA Mini Kit
(Life Technologies). mRNA levels were determined by either
TaqMan qPCR with gene-specific primers and probes from the
Universal Probe Library (Roche), or by SYBR green qPCR, using
the appropriate one-step RT-qPCR kits (Thermofisher). Expres-
sion levels were normalised to the housekeeping cellular gene
hypoxanthine phosphoribosyltransferase 1 (HPRT) and calibrated
to mock-transfected cells. qPCR was carried out in duplicate for
each sample, and normalised expression levels averaged.
Phenotype Validation by siRNA Deconvolution
The phenotype observed in the primary screen was confirmed
for a subset of candidate genes with deconvoluted siRNA
SMARTpools. The four individual siRNAs targeting different
regions of each gene were diluted to 0.3 mM in 1x siRNA buffer
and dispensed to 96-well plates in triplicate. Transfection and,
48 h later, infection with VACV-A5eGFP was carried out as
described above. At 0 and 48 h post infection fluorescence was
measured using a Synergy HT plate reader (BioTek). The
experiment was carried out three times to produce a dataset of
three biological replicates each containing three technical repli-
cates. The data were analysed using mixed models [18] fitting
gene, time-point gene*time interaction and first time-point value
as fixed effects. Values observed at the first time-point were fitted
as a ‘baseline covariate’ in order to increase the sensitivity of the
analysis. The repeated experiments were fitted as random effects,
causing the variation in results between the repeated experiments
to be taken into account when testing statistical significance.
Differences between the amount of fluorescence present in wells
treated with each siRNA and wells treated with a non-specific
siRNA (targeting the HSV-1 gene VP16) were tested within the
mixed models using t-tests. Groups of genes were tested on
separate plates and each of the groups were analysed using a
separate mixed model. A phenotype was considered confirmed if
two or more of the four siRNAs resulted in a p-value of 0.05 or
less.
Host Factors Influencing Vaccinia virus Replication
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Plaque Assay
Six wells of a 96 well plate were transfected with a siRNA
SMARTpool and, 48 h later, infected with VACV-A5eGFP as
described above. At 24, 36 and 48 h post infection cells were
scraped into the overlying media, collected and then frozen and
thawed three times and sonicated for 30 seconds (Misonix
sonicator 3000). The resultant lysate was titrated on BS-C-1 cell
monolayers and virus titre quantified as plaque forming units
(PFU) per ml [19].
Gene Set Overrepresentation Analysis
Enrichment analysis was performed with respect to pathway-
and GO-based gene sets defined in MSigDB [20], as well as with
respect to gene sets derived from protein complexes curated in the
CORUM [21] and PIN [22] databases. Specifically, the genes
were sorted based on the screening data, and then the propensity
of gene sets towards pro- or anti-viral activities were sought out
using rank-sum tests with multiple testing [23].
Comparison with Cellular Expression Data
The three gene expression data sets used in the analyses were
data set A (GSE11238, a microarray of VACV infected HeLa cells
(http://www.be-md.ncbi.nlm.nih.gov/projects/geo/query/acc.
cgi?acc =GSE11238)), data set B (GSE24125, a microarray of
macrophages, monocytes and fibroblasts [24]), and data set C
(SRA017695, a RNA-seq based analysis of gene expression in
Figure 1. Identification of HFs for Vaccinia virus replication by RNA interference screen. (a) Schematic of the experimental workflow used
to screen the replication of VACV with the druggable RNAi library. (b) Comparison of the level of fluorescence of the control siRNAs used in the
primary screen. Wells were transfected with siRNA targeting PRK-AB1 and eGFP (known to downregulate VACV-A5eGFP growth), two negative
controls (mock transfection and RSCF siRNA) and two non-specific siRNAs (targeting VP16 or VP11/12 from Herpes simplex virus type 1). Error bars
indicate the standard error of the mean. (c) Correlation between level of fluorescence and amount of virus present. HeLa cells were mock transfected
or transfected with siRNA which is not processed by the RISC machinery (RSCF) or which knocks down a strong VACV pro-viral factor (FBXL11). After
48 h cells were infected with VACV-A5eGFP at low multiplicity of infection (MOI 0.05). At 24, 36 and 48 h post infection fluorescence was measured (y
axis) before the cells were collected for titration using a plaque assay (x axis). Correlation (Pearson product moment correlation coefficient) between
the two datasets = 0.86. (d) Plot of sorted z-scores representing the level of fluorescence associated with each of the 6 719 siRNA SMARTpools in the
screen (average of 8 replicates). siRNA pools targeting genes of particular interest are marked.
doi:10.1371/journal.pone.0098431.g001
Host Factors Influencing Vaccinia virus Replication
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VACV infected HeLa cells [25]). For comparison of the RNAi hit
list with the two HeLa cell based cellular expression data sets, the
differential expression-based rank for each gene (g) was obtained in
each condition (i.e. a timepoint in a data set) and then a
‘‘summerisation q-value’’ qg was calculated which reflects how
unexpectedly high the ranks are (using order statistics; in particular
the rank of the third 4-quantile). Therefore qg quantifies how
unexpectedly often g is among the most strongly regulated genes
(up or down).
Identification of Vaccinia virus Host Factors by RNA
Interference Screen
To identify HFs that influence VACV replication we used a
druggable genome small interfering RNA (siRNA) library
(Dharmacon) in a high-throughput screen. This library targets
genes that are considered potential candidates for therapeutics
(Figure 1a). Briefly, SMARTpool siRNAs (a mix of 4 siRNAs per
gene) targeting 6 719 genes were distributed into 384-well plates
and reverse-transfected into HeLa cells. Cells were infected 48 h
post-transfection at a low multiplicity of infection (MOI 0.05) with
the VACV strain VACV-A5eGFP. After 48 h (thus allowing
multiple complete virus replication cycles), eGFP fluorescence was
quantified as a measure of infection and compared to controls in
order to determine the effect of individual gene depletion on
VACV replication. Two positive siRNA controls known to
downregulate VACV-A5eGFP growth (targeting PRK-AB1 and
eGFP), two negative controls (mock transfection and RSCF siRNA
which is not processed by the RISC machinery) and two non-
specific siRNAs (targeting VP16 or VP11/12 from Herpes simplex
virus type 1) were included in duplicate in each plate (Figure 1b).
To confirm that the measurement of virus-expressed fluorescence
was a reliable marker of viral replication, fluorescence was
correlated to virus-titre, as determined by standard plaque assay,
over a range of time-points post-infection after treatment with
control or inhibitory siRNAs (Figure 1c). This resulted in a
Pearson product moment correlation coefficient of 0.86, confirm-
ing that fluorescence was a reliable determinant of virus
replication. The entire druggable screen was repeated four times
in duplicate to generate a robust primary data set of eight
replicates. Pairwise agreement comparing the levels of fluores-
cence across the eight replicates revealed good reproducibility
(median Spearman’s coefficient 0.55). One replicate of the VACV-
infected cells was analysed by automated microscopy using an
OPERA high content screening system and Acapella High
Content Imaging and Analysis software to quantify the number
of cells present in each well. A total of 403 siRNA pools (6% of the
total) were associated with a significant reduction in cell number
(Figure 1a). These were removed from further analysis and are
listed in Table S1 in File S1.
The fluorescence data from the remaining wells in the primary
screen was normalised platewise using the robust z-score method
[17]. A summary value was calculated for each gene by taking the
mean across the replicates, and these values were converted to z-
scores which were corrected for the number of cells in the well to
produce the level of fluorescence per cell for each siRNA. A
negative z-score indicated a reduction in VACV replication and a
positive z-score indicated an increase in VACV replication
(Figure 1d). The two positive controls (siRNA targeting PRKAB1
and eGFP) produced strongly negative z-scores as expected. The
median level of fluorescence (z-score of 0) was very close to the
level of fluorescence seen in wells transfected with the non-specific
siRNA (negative control), indicating that roughly half of the
siRNA pools caused an increase in fluorescence and half caused a
decrease. A ‘‘hit’’ was defined as a siRNA pool which generated a
z-score of $2 or #–2. Using these criteria, a hitlist of 302 HFs
(4.5% of the total) was generated, consisting of 153 pro-viral HFs
which inhibited replication upon depletion and 149 anti-viral HFs
which increased replication upon depletion (Table S2 in File
S1).
Validation of Primary RNAi Screen Data
To confirm the effect of the siRNA SMARTpools on mRNA
levels, a subset of SMARTpools were transfected into HeLa cells
and after 48 h, total RNA extracted and subjected to a
quantitative RT-PCR to determine the level of mRNA of the
targeted gene. 62 genes out of 80 tested (78%) had their transcript
level reduced by 50% or more, indicating that the majority of the
SMARTpools functioned as expected (Table S3 in File S1).
To confirm the effect of gene depletion on VACV replication a
subset of HFs, chosen on the basis of their potential for further
investigation, were tested using the four individual, deconvoluted
siRNAs of each SMARTpool. The level of viral fluorescence was
compared to that seen with non-specific siRNA and a statistically
significant reduction or increase in fluorescence (p,0.05) induced
by at least 2 individual siRNAs from the original SMARTpool was
required for confirmation of the hit. Overall 38 (53%) out of 72
candidate genes tested by this method were successfully confirmed
(Table S4 in File S1). This level of validation is commensurate
with similar RNAi screens of viral replication which have reported
confirmation of between 38% and 83% of primary screen hits
[26–33].
Within our deconvoluted dataset the validation level of putative
pro-viral HFs was notably higher than that for the anti-viral HFs.
Only 30% of the anti-viral hits (7/24) were successfully validated
in comparison to 69% of the pro-viral hits (24/35) and 54% of the
siRNA pools with no effect in the primary screen (7/13). One
potential reason for the lower validation rate of the anti-viral hits
might be that the dynamic range of the virus replication assay is
such that inhibitory effects are more easily demonstrated, as under
normal replication conditions virtually all cells in the well became
infected by 48 h post infection (data not shown) suggesting the
system reached near saturation. To examine this further, the effect
of selected siRNAs on traditional viral growth curves was tested
and correlated with their perturbation of fluorescence in the
primary screen. HeLa cells were transfected with each one of 6
siRNA SMARTpools (upregulatory MAP3K14, control VP16,
and downregulatory TRIP, PPAP2A, VPS52 and CCT7) and
infected with VACV-A5eGFP at an MOI of 0.05 after 48 h.
Analysis of virus titre at 12 h intervals by plaque assay found the
endpoint titres correlated very closely with the z-score obtained
from the primary RNAi screen (Figure 2), further validating the
robustness of the primary screen. Notably, however, whilst the
inhibitory siRNAs decreased the maximum virus titre by between
13- (CCT7) and 5-fold (VPS52) the siRNA treatment directed
against a candidate antiviral HF (MAP3K14) only increased peak
virus titre by 3-fold. Thus the response of the system is more suited
to detecting inhibitory perturbation, with relatively reduced
sensitivity for detection of individual anti-viral HFs.
The list of 302 individual HFs was analysed for genes already
known to influence VACV replication. Numerous examples were
found including clathrin and proteins involved in Golgi vesicular
trafficking, both of which are required for the production of
enveloped VACV forms [34,35], as well as multiple components of
the AMPK complex which has been shown to aid VACV entry
[36]. In addition the signalling pathway regulating protein TRAF2
was identified in the screen as a pro-viral hit; further work
demonstrated that it promoted rapid VACV entry [37]. The
identification of known host factors for VACV and our follow-up
Host Factors Influencing Vaccinia virus Replication
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Results and Discussion
identification of the role of TRAF2 in VACV replication supports
the reliability and significance of this RNAi screen dataset.
Overall, eight replicates of a genome-wide RNAi screen of
multiple VACV replication cycles identified 302 cellular genes,
consisting of 153 HFs that positively support VACV replication
and 149 HF with anti-viral effects.
Host Factors Common to other VACV Screens
To prioritise investigations of the 302 potential VACV HFs, the
candidate genes were compared to the hit lists of other viral RNAi
screens, including two recently published VACV screens [32,38].
The methodology in the previously published VACV screens
varied considerably; Mercer et al [32] measured the growth of a
thymidine-kinase-deficient VACV (strain Western Reserve) after
only 8 h of infection, thereby identifying cellular proteins involved
in the initial stages of virus replication but excluding analysis of
viral spread. They reported 188 pro-viral HF but no anti-viral
HFs. A second screen by Sivan et al [38] used the VACV strain
IHD-J (which has a point mutation that accelerates the release of
progeny virions from the cell surface) to identify genes which
influenced viral replication after 18 h of infection, thus measuring
the entire replication cycle with emphasis on viral spread. They
reported 576 pro-viral and 530 anti-viral HFs. The overlap
between the hit lists reported by the three VACV RNAi studies
(Mercer et al, Sivan et al, and this study) is depicted in Figure 3a
and b and the HFs common to two studies are listed in Table S5
in File S1. The number of overlapping hits between two of the
screens ranged from 3 to 13 and no HFs were common to all three
VACV studies. A small number of common hits between siRNA
screens of the same virus is a frequent finding [39,40] and, given
the variation in methodology between the three VACV screens
(including viral strain, infection time, and data analysis), is not
surprising. However, comparison of the enriched functions and
pathways identified in each of the three VACV screens revealed
marked similarities (discussed below), demonstrating the power of
comparative screening approaches to identify significant cellular
pathways involved in virus replication.
Host Factors Common with other Viruses
Genome-scale siRNA screens have been carried out for many
viruses other than VACV, including HIV-1 [41–43], West Nile
Virus (WNV) [44], Hepatitis C Virus (HCV) [30,45], Vesicular
Stomatitis Virus (VSV) [29], Borna Disease Virus [46], enterovi-
ruses [27], Dengue virus [28], herpes simplex virus 1 (HSV-1) [33]
and influenza A virus [26,31,47]. Host factors common to two or
more of these screens could represent broadly acting cellular
proteins with a generalised effect on viral replication. A
Figure 2. Validation of Vaccinia virus HFs. (a) Validation of primary
screen hits using plaque assays. siRNA SMARTpools targeting five genes
identified in the primary RNAi screen as modulating VACV growth (one
anti-viral factor MAP3K14 and four pro-viral factors TRIP, PPAP2A, VPS52
and CCT7), and one non-specific SMARTpool (VP16) were transfected
into HeLa cells and, after 48 h, infected at low MOI (0.05) with VACV-
A5eGFP. At 12 h intervals, cells were collected and the amount of virus
present calculated using a plaque assay. Results obtained in the primary
RNAi screen are plotted on the right hand axis for comparison.
doi:10.1371/journal.pone.0098431.g002
Figure 3. Identification of anti and pro-viral HFs common to
multiple RNAi viral screens. Venn diagram showing the (a) pro-viral
and (b) anti-viral hits common to at least two VACV RNAi screens and (c)
hits common to the VACV screen reported in this study and three
published influenza A RNAi screens with a total of 662 hits [26,31,47]
and three published HIV RNAi screens with a total of 826 hits [41–43].
doi:10.1371/journal.pone.0098431.g003
Host Factors Influencing Vaccinia virus Replication
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comparison of the VACV HFs identified in this screen with those
identified in other viral screens found a small overlap with WNV,
VSV, Borna Disease virus and Dengue virus, whilst 21 VACV
HFs were shared with HSV-1, 17 with influenza A virus and 13
with HIV-1 (Figure 3c). A list of overlapping genes can be found
in Table S6 in File S1.
Amongst the factors in common, the nucleocytoplasmic
transport factor NUP98 was identified as a proviral hit in the
VACV screen reported here as well as HIV, HSV-1 and influenza
A virus screens [26,31,33,42]. It is located at both the cytoplasmic
and the nuclear faces of the central channel of the nuclear pore
complex (NPC) [48], is involved in Rev-dependent RNA export
during HIV infection [49], and has been shown to play both pro-
and anti-viral functions during influenza A virus infection
[31,50,51]. NUP98 was a somewhat unexpected proviral hit in
our screen since poxvirus replication and assembly occur in the
cytoplasm. However the two VACV RNAi screens published
recently also identified a number of nuclear pore proteins as pro-
viral, with one screen demonstrating that knockdown of NUP62
strongly inhibited viral morphogenesis [38]. The number of
nuclear pore proteins now identified as pro-viral HFs strongly
suggests poxviruses require functional nuclear membrane trans-
port for efficient replication.
Another HF that affects both VACV and influenza A virus
replication is MAP2K3 (also known as MKK3 and MEK3), which
activates the p38 MAPK signalling pathway and is involved in low
pH-dependent entry of influenza virus and VSV [31,47]. VACV
also has a low pH-dependent entry mechanism [52] which may be
similarly reliant on MAP2K3. Alternatively, it may be required to
activate the p38 MAPK pathway to promote cell survival post
infection [14].
In contrast, IFITMs (interferon inducible transmembrane
proteins) have been identified in functional genomic screens as
mediating resistance to influenza A virus, Dengue virus and West
Nile virus infection in vitro and in vivo [26,53] as well as Marburg
and Ebola viruses, SARS-coronavirus [54] and HIV [55]. These
proteins prevent entry of viruses at the plasma membrane,
endosomes and lysosomes [56], however none had an effect on
VACV replication in our screen, suggesting VACV is resistant to
the repressive effect of this protein family (Figure 1d).
Transcriptional Modulation of Vaccinia virus Host Factors
To determine whether the expression of HFs identified by
RNAi is modulated by VACV, the RNAi hit list was compared to
previously published transcriptional profiling data sets performed
on cells infected with VACV. Three available expression profiling
data sets (designated A, B and C, see Materials and Methods for
sources) which used different cells, virus isolates and time points
were compiled and compared. Correlation was mainly limited to
intra-data set measurements (i.e. different time points or cell lines
within a data set) with some examples of agreement between data
sets A and C, both of which used HeLa cells. To test whether there
was a general propensity of HFs to be differentially expressed in
virus-infected cells the distribution of the 302 RNAi hits was
compared to that of the whole RNAi screen in these three
transcriptional profiling data sets. No significant tendency of pro-
viral HFs to be up-regulated or anti-viral HFs to be downregulated
was detected (data not shown). Subsequently the expression of
individual HFs was examined using the transcriptional profiling
data of the two HeLa-based studies (A and C). This revealed
specific examples of HFs which are differentially expressed in
virus-infected cells (Figure 4). Four pro-viral HFs (RUNX1,
eIF3C, HBEGF, and ADM) were significantly upregulated in
VACV-infected HeLa cells (q,0.05), suggesting that VACV might
promote expression of these proteins to assist viral replication and
spread. RUNX1 is a subunit of the transcription factor CBF which
regulates critical processes in both myeloid and lymphatic
haematopoiesis. Chromosomal translocations and mutations of
RUNX1 are among the most frequent genomic abnormalities in
different types of leukaemia [57]. Furthermore, a genome-wide
association study found a genetic polymorphism in RUNX1 to be
associated with the serological response to VACV vaccination
(Dryvax vaccine, Wyeth Laboratories) in African-Americans. This
suggests that the RUNX1 polymorphism may influence replication
and viral gene expression of the live-attenuated vaccine in vivo
which causes differences in the strength of the adaptive immune
response [58], a hypothesis supported by our identification of
RUNX1 as a pro-viral VACV HF.
In addition to upregulated pro-viral HFs, opposite examples
were also identified, with two anti-viral HFs (ANGPTL4, RBAK)
significantly upregulated and one pro-viral HF (SAP18) downreg-
ulated in VACV-infected cells. This lack of correlation between
functional HFs and gene expression at the transcriptional level
serves to underscore the complexity of virus-host interactions and
highlights the need for further follow-up studies.
Functional and Pathway Analyses of Vaccinia Virus Host
Factors
To assess further the role of candidate HFs and associated
functions and pathways in VACV replication, an overrepresenta-
tion analysis of the complete VACV RNAi data set was performed
with respect to pathway- (Figure 5a) and GO- (Figure 5b) based
gene sets as defined in the MSigDB database, as well as from
curated protein complexes defined in the CORUM [21] and PIN
[22] databases (Figure 5c). Translation was the most strongly
enriched theme in all these analyses, particularly the eIF3
complex. Poxviruses are known to utilise the host translation
machinery for production of viral proteins therefore the enrich-
ment of translation as a pro-viral theme is a validation of the
screening method. The cellular translation machinery has been
highlighted in other viral RNAi screens as essential for VSV [29]
and hepatitis C virus [45] and HSV-1 [33].
More interestingly, transcriptional initiation and general RNA
polymerase II transcription factor activity were identified in the
functional analysis of the RNAi screen as significantly over-
represented anti-viral GO-based gene sets (Figure 5b). Sevin et al
[38] also reported that interference with DNA-dependent RNA
polymerase II pathways enhanced VACV spread. Our work
identified individual anti-viral HFs involved in transcription such
as MAZ (an inflammatory responsive transcription factor also
known as SAF1), and the transcription factor E2F2. Inspection of
individual confocal images taken at 48 h pi of cells depleted of
these factors showed notably brighter accumulations of eGFP-
labelled virus, in line with the positive z-scores from the overall
primary screen (Figure 6a). Orthopoxvirus infection results in a
rapid shut down of cellular transcription, with a marked reduction
in the amount of host mRNA present as early as 2 h post infection
[25,59,60]. This effect is believed to result from cessation of host
mRNA synthesis and degradation of cellular mRNA transcripts.
The viral proteins involved in this shut-off of host cell transcription
have not been identified, although D9 and D10 have been
implicated [61,62]. In contrast to viral translation which is
dependent on host proteins, VACV encodes its own transcription
enzymes so is largely unaffected by a general repression of cellular
transcription [63]. Therefore VACV-induced downregulation of
host transcription prevents the host cell from transcribing anti-
viral, pro-inflammatory gene programmes, such as the NF-kB
cascade, while having a minimal negative effect on viral
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Figure 4. Transcriptional modulation of Vaccinia virus HFs. Plot of seven VACV HFs identified in the RNAi screen that are also strongly
transcriptionally regulated in VACV infected cells. The x-axis represents the level of fluorescence in the RNAi screen (viral replication) expressed as a z-
score with pro-viral genes to the left and anti-viral genes to the right. The y-axis represents the relative expression of the seven genes in VACV
infected cells.
doi:10.1371/journal.pone.0098431.g004
Figure 5. Functional characterization of Vaccinia virus HFs. Gene sets identified by over-representation analysis. Gene sets were identified
using (a) pathway- and (b) GO-based gene sets as defined in the MSigDB database, or (c) protein complexes defined in the CORUM [21] and PIN [22]
databases. All significantly overrepresented gene sets (–log10(q-value).0.1) are shown. Each row shows the ranks of genes from a particular gene set
that were present in the RNAi screen. Each tick mark denotes the place of a particular gene from that gene set, placed at the appropriate position in
the distribution. Genes were sorted from left to right from most pro-viral to most anti-viral. The red and blue colours of the ticks are used for visual
contrast. A green diamond is used to denote the median rank of the genes in the set.
doi:10.1371/journal.pone.0098431.g005
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transcription. Whilst VACV has developed mechanisms to shut off
host transcription, these data show that virus replication is
improved when transcription is impaired prior to infection. Thus,
despite the efforts of the virus to shut off host transcription, some
anti-viral effect of this pathway persists in VACV infected cells.
Two members of the septin protein family (septin 1 and MSF/
septin 9) were identified in the RNAi screen as anti-viral HFs
(Figure 6b). MSF/septin 9 co-purifies from cells with three other
septin proteins (NEDD5/septin 2, CDC10/septin 7 and septin
11), suggesting they form a functional complex [64]. These were
therefore grouped in the pathway analysis, resulting in a significant
Figure 6. Analysis of pro- and anti-viral cellular pathways. Left hand panels show selected fluorescence images of infected HeLa cells
transfected with the indicated siRNAs at 48h post infection. Blue =DAPI (DNA stain), red = phalloidin (actin cytoskeleton) and green =VACV-A5eGFP.
The z-score of each siRNA is indicated in the bottom right of each image. The right hand panels show the plot of sorted z-scores from the primary
screen with the position of genes of interest marked. (a) Transcriptional proteins inhibitory for VACV replication (b) Anti-viral function of septins (c)
Genome maintenance and DNA repair proteins inhibitory for VACV replication (d) The AMP-activated kinase complex is involved in VACV replication.
doi:10.1371/journal.pone.0098431.g006
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over representation (q= 0.1) (Figure 5c). Consistent with this,
depletion of NEDD5/septin 2, septin 7 and septin 11 all increased
virus replication although not to the stringent cut-off used here to
define a ‘hit’ (Figure 6b). Deconvoluted siRNAs targeting septin
11 mRNA confirmed the enhancement of virus replication,
although results with the other family members were more
variable (Table S4 in File S1). Septin 11 has also been identified
as a proviral hit in a recently reported VACV siRNA screen [38].
Septins are conserved GTP-binding proteins which act as dynamic
scaffolds for recruitment of other proteins. They are involved in
actin and microtubule function, cytokinesis, cell movement and
vesicle trafficking [65]. Interestingly, they can be recruited
together with autophagic proteins to ‘‘cage’’ Shigella flexneri in the
cytosol of infected cells, restricting bacterial dissemination [66].
The cage assembly is linked with actin polymerisation activity of S.
flexneri, suggesting that a similar mechanism may be employed by
the host cell to ‘‘cage’’ VACV virions (which activate actin
polymerisation both early and late in the replication cycle [67,68])
and thus invoke an anti-viral effect.
Two groups of genes involved in DNA replication and repair
were highlighted in the pathway analysis as having anti-viral
properties (Figure 5c). The PCNA-MutSa-MutLa-DNA complex
(PCNA, MSH2, PMS2, and MLH1) and the BRCA1-associated
genome surveillance complex (RFC4, BRCA1, BLM, RFC1,
MSH2 and MLH1) both promoted virus replication when
individual group members were downregulated (Figure 6c).
These pathways are both involved in DNA damage signalling and
repair [69,70], a cellular process which is targeted by numerous
viruses [71]. Specifically, DNA damage signalling pathways act as
a host defence mechanism in poxvirus infection, detecting and
responding to foreign poxviral DNA and inducing intrinsic
apoptosis [72]. The identification of the PCNA and BRCA1 gene
sets as strongly anti-poxviral HFs in the RNAi screen suggests they
are a part of this, or a similar, defence mechanism.
The AMP-activated kinase complex (AMPK) is a key regulator
of energy metabolism. It is activated by a reduction in ATP which
prompts phosphorylation of many target proteins, resulting in the
activation of catabolic pathways and inhibition of anabolic
pathways [73]. It has also been linked to regulation of the actin
cytoskeleton [74]. AMPK is a heterotrimer comprising a catalytic
a subunit and regulatory b and c subunits. In mammals each
subunit has several isoforms (PRKAA1, PRKAA2, PRKAB1,
PRKAB2, PRKAG1, PRKAG2, and PRKAG3) [73]. The
druggable RNAi screen reported here screened all seven genes
and identified three (PRKAA2, PRKAB1, and PRKAB2) as
promoters of VACV replication whose depletion led to fewer and
dimmer accumulations of cytoplasmic eGFP (Figure 6d). This
result is in broad agreement with a recently published RNAi
screen of 440 cellular kinases and phosphatases in a non-
permissive Drosophila cell model of VACV infection [36], which
identified seven hits including three AMPK subunits.
Conclusion
This study performed a loss of function analysis of HFs involved
in VACV infection using RNAi. Previously identified host
pathways and protein complexes which aid VACV replication,
such as translation and the AMPK complex proteins, were
highlighted in the RNAi screen. In addition, however, a range of
novel host pathways and proteins were identified that influenced
VACV infection, such as the DNA damage and repair pathways,
the septin family of proteins, MAP2K3 and NUP98. As many of
the genes targeted in this RNAi screen have a known drug
inhibitor, this work yields a list of HFs that can potentially be
targeted by novel therapeutics.
Supporting Information
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siRNAs which caused significant cell death. Table S2, The 302
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three different VACV RNAi screens. Table S6, Overlap of HFs
between VACV and other viral RNAi screens.
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